Security
DCOY · Decoy Therapeutics Inc.
DCOYNASDAQCommon stockCurrentCIK 1615219Updated Sep 27, 2026
Name history
Salarius Pharmaceuticals, Inc. · through Jan 9, 2026Flex Pharma, Inc. · through Jul 22, 2019
DCOY price & chart
Loading TradingView…
NASDAQ:DCOY on TradingView ↗About the company
Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across multiple viruses. Built on the proprietary IMP(3)ACT platform, which combines AI-assisted design and rapid synthesis, Decoy develops peptide antivirals designed to move faster into the clinic and expand what is possible in viral prevention and treatment. The company's lead candidates target multiple respiratory viruses, addressing the health and societal burden of viral disease.
In the news
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing ↗
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
4 filing
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 11,056,707Source | 3,022,974Source | 6,586,523Source | 14,650,799Source |
| Property, Plant and Equipment, NetUSD | 40,559Source | — | — | — |
| GoodwillUSD | — | — | — | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,709,937Source | 2,434,528Source | 5,899,910Source | 12,106,435Source |
| Assets, CurrentUSD | 10,985,160Source | 2,987,562Source | 6,519,673Source | 14,520,298Source |
| Prepaid Expense and Other Assets, CurrentUSD | 275,223Source | 553,034Source | 619,763Source | 803,373Source |
| Other Assets, NoncurrentUSD | 30,988Source | 35,412Source | 66,850Source | 130,501Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,167,738Source | 1,511,279Source | 1,299,241Source | 4,266,191Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 53Source | 144Source | 393Source | 225Source |
| Additional Paid in CapitalUSD | 100,331,014Source | 83,435,169Source | 81,634,730Source | 74,189,531Source |
| Retained Earnings (Accumulated Deficit)USD | -94,442,098Source | -81,923,618Source | -76,347,841Source | -63,805,148Source |
| Stockholders' Equity Attributable to ParentUSD | 5,888,969Source | 1,511,695Source | 5,287,282Source | 10,384,608Source |
| Liabilities and EquityUSD | 11,056,707Source | 3,022,974Source | 6,586,523Source | 14,650,799Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,167,738Source | — | — | — |
| Accounts Payable, CurrentUSD | 940,586Source | 936,994Source | 602,853Source | 2,858,330Source |
| Additional Financial Items | ||||
| Restricted Cash and Investments, CurrentUSD | 3,000,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 7,151Source | 4,424Source | 10,051Source | 6,677Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 219,058Source | 273,730Source | 524,838Source | 796,803Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -1,167,068Source | 334,141Source | -2,255,477Source | 1,312,735Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,827,188Source | -4,525,337Source | -12,846,137Source | -17,595,321Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 764,735Source | — | 0Source | -1,500,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 12,337,862Source | 1,059,955Source | 6,639,612Source | 1,987,376Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,275,409Source | -3,465,382Source | -6,206,525Source | -17,107,945Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,709,937Source | 2,434,528Source | 5,899,910Source | 12,106,435Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,800Source | 10,643Source | 14,754Source | 0Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 3,727,816Source | 4,964,289Source | 5,721,197Source | 7,138,403Source |
| GoodwillUSD | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 8,865,909Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -12,518,480Source | -5,575,777Source | -12,542,693Source | -31,607,956Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -5,575,777Source | -12,542,693Source | -31,607,956Source |
| Operating ExpensesUSD | 12,613,952Source | 5,734,316Source | 12,894,944Source | 31,841,140Source |
| Restricted Cash and Investments, CurrentUSD | 3,000,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source |
| Operating Income (Loss)USD | -12,613,952Source | -5,734,316Source | -12,894,944Source | -31,841,140Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -12,518,480Source | -5,575,777Source | -12,542,693Source | -31,607,956Source |
| Earnings Per Share, BasicUSD per share | -129.1Source | -5.79Source | -3.84Source | -14.88Source |
| Earnings Per Share, DilutedUSD per share | -129.1Source | -5.79Source | -3.84Source | -14.88Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 96,967Source | 962,210Source | 3,264,620Source | 2,124,511Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 96,967Source | 962,210Source | 3,264,620Source | 2,124,511Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 3,727,816Source | 4,964,289Source | 5,721,197Source | 7,138,403Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 8,865,909Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -129.1Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -129.1Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | 95,472Source | 158,539Source | 352,251Source | 218,730Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -5,575,777Source | -12,542,693Source | -31,607,956Source |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | -12,518,480Source | — | — | — |
| Operating ExpensesUSD | 12,613,952Source | 5,734,316Source | 12,894,944Source | 31,841,140Source |
| Research and Development ExpenseUSD | 368,170Source | 770,027Source | 7,173,747Source | 15,836,828Source |
Offerings
Registration 333-297381
Registration 333-296773
Filing attachments
dcoy-ex4_1.htm · 8-K · 2026-09-23
Exhibit 4.1 WARRANT TO PURCHASE SHARES OF COMMON STOCK DECOY THERAPEUTICS INC. Warrant Shares: 2,368,868 Initial Exercise Date: September 23, 2026 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) …
Read attachment ↗dcoy-ex99_1.htm · 8-K · 2026-09-23
Exhibit 99.1 Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules Houston, TX., September 22, 2026 - Decoy Therapeutics, Inc. (NASDAQ: DCOY) (“the Company” or “Decoy”), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs(TM)), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced its entry into a warrant inducement ag…
Read attachment ↗dcoy-ex99_2.htm · 8-K · 2026-09-23
Exhibit 99.2 Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release Houston, TX., September 22, 2026 - Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the “Company” or “Decoy”), today issued a correction to its press release dated September 22, 2026 announcing the Company’s warrant inducement transaction. The original press release incorrectly stated that the new unregistered warrants to purchase up to 2,368,868 shares of the Company’s common stock to be issued in…
Read attachment ↗dcoy-ex4_1.htm · 8-K · 2026-06-29
EX-4.1 2 dcoy-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUAN…
Read attachment ↗dcoy-ex4_2.htm · 8-K · 2026-06-29
EX-4.2 3 dcoy-ex4_2.htm EX-4.2 EX-4.2 Exhibit 4.2 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE S…
Read attachment ↗dcoy-ex4_3.htm · 8-K · 2026-06-29
EX-4.3 4 dcoy-ex4_3.htm EX-4.3 EX-4.3 Exhibit 4.3 Warrant Certificate No. THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE S…
Read attachment ↗